Skip to main content

BTB and CNC homology 1 (Bach1) induces lung cancer stem cell phenotypes by stimulating CD44 expression



Growing evidence suggests that cancer stem cells (CSCs) are responsible for cancer initiation in tumors. Bach1 has been identified to contribute to several tumor progression, including lung cancer. The role of Bach1 in CSCs remains poorly known. Therefore, the function of Bach1 on lung CSCs was focused currently.


The expression of Bach1, CD133, CD44, Sox2, Nanog and Oct4 mRNA was assessed using Real-Time Quantitative Reverse Transcription PCR (RT-qPCR). Protein expression of Bach1, CD133, CD44, Sox2, Nanog, Oct4, p53, BCL2, BAX, p-p38, p-AKT1, c-Fos and c-Jun protein was analyzed by western blotting. 5-ethynyl-29-deoxyuridine (EdU), colony formation, Flow cytometry analysis and transwell invasion assay were carried out to analyze lung cancer cell proliferation, apoptosis and invasion respectively. Tumor sphere formation assay was utilized to evaluate spheroid capacity. Flow cytometry analysis was carried out to isolate CD133 or CD44 positive lung cancer cells. The relationship between Bach1 and CD44 was verified using ChIP-qPCR and dual-luciferase reporter assay. Xenograft tumor tissues were collected for hematoxylin and eosin (HE) staining and IHC analysis to evaluate histology and Ki-67.


The ratio of CD44 + CSCs from A549 and SPC-A1 cells were significantly enriched. Tumor growth of CD44 + CSCs was obviously suppressed in vivo compared to CD44− CSCs. Bach1 expression was obviously increased in CD44 + CSCs. Then, via using the in vitro experiment, it was observed that CSCs proliferation and invasion were greatly reduced by the down-regulation of Bach1 while cell apoptosis was triggered by knockdown of Bach1. Loss of Bach1 was able to repress tumor-sphere formation and tumor-initiating CSC markers. A repression of CSCs growth and metastasis of shRNA-Bach1 was confirmed using xenograft models and caudal vein injection. The direct interaction between Bach1 and CD44 was confirmed by ChIP-qPCR and dual-luciferase reporter assay. Furthermore, mitogen-activated protein kinases (MAPK) signaling pathway was selected and we proved the effects of Bach1 on lung CSCs were associated with the activation of the MAPK pathway. As manifested, loss of Bach1 was able to repress p-p38, p-AKT1, c-Fos, c-Jun protein levels in lung CSCs. Inhibition of MAPK signaling remarkably restrained lung CSCs growth and CSCs properties induced by Bach1 overexpression.


In summary, we imply that Bach1 demonstrates great potential for the treatment of lung cancer metastasis and recurrence via activating CD44 and MPAK signaling.


Lung cancer is a malignant tumor with a high rate of morbidity and mortality worldwide. Previous studies have reported that non-small cell lung cancer (NSCLC) accounts for almost 85% of lung cancer cases [1]. The main reason for treatment failure and mortality in NSCLC is cancer cell invasion and metastasis [2, 3]. Although it has been confirmed that multiple tumor-related genes are involved in the modulation of NSCLC development, the detailed molecular mechanism of NSCLC remains unclear.

Recently, it has been reported that there is a small group of cells within tumors that can play an important role in cancer resistance and participate in tumor progression and metastasis, hence are called cancer stem cells [4]. It has been reported that leukemia stem cells were the first CSCs discovered [5]. Cancer stem cells are widely recognized in many types of cancers, such as lung cancer, liver cancer, and pancreatic cancer [6,7,8]. Lung CSCs are critical for lung cancer metastasis and drug resistance. For example, CD44 is functionally important for activating lung CSCs by regulating the Wnt/β-catenin-FoxM1-Twist pathway [9]. Previously, we reported that epigallocatechin-3-gallate (EGCG) represses CSC-like properties by modulating miR-485 and CD44 in cisplatin-resistant A549 cells [10]. Nuclear-enriched abundant transcript 1 (NEAT1) induces CSC-like traits in lung cancer cells by activating Wnt signaling [11]. Therefore, targeting lung CSCs may be useful for lung cancer therapy.

Bach1 is a crucial transcriptional factor that plays an important role in oxidative stress, the cell cycle, hematopoiesis, and immunity [12,13,14]. Bach1 has been shown to function as an inducer of metastatic genes in breast cancer, including CXCR4 and MMP1 [15, 16]. Higher Bach1 levels indicate a higher risk of human cancers, such as colorectal cancer, glioblastoma, and lung cancer [17,18,19]. Bach1 stabilization by antioxidants can induce lung cancer [20]. However, the detailed function of Bach1 in lung cancer stem cells remains unclear.

In this study, we investigated the role of Bach1 in lung cancer. Bach1 is highly expressed in lung CSCs and its knockdown repressed lung CSC growth and metastasis. In addition, Bach1 interacts with CD44 and contributes to lung CSC migration and invasion. Bach1 also activates the expression of genes related to the MAPK signaling pathway. Therefore, our findings indicate that Bach1 can serve as an important transcriptional regulator of lung CSC development. The investigation was conducted to develop promising treatment strategies and improve the effectiveness of lung CSCs.

Materials and methods

Cell culture

A549, SPC-A1 and H1299 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). A549, SPC-A1 and H1299 cells were maintained at 37 °C in 5% CO2-humidified air in RPMI 1640 medium containing 10% FBS (Sigma-Aldrich, St. Louis, MO, USA), 100 U/mL penicillin, and 100 mg/mL streptomycin/penicillin. CD44 + cells were isolated using the CD44 microbead isolation kit (Miltenyi Biotec, Auburn, CA, USA).

5-Eyhynyl-2′-deoxyuridine (EdU) staining assay

Cell proliferation was evaluated via EdU staining using a Cell-Light™ EdU Apollo® 488 In Vitro Imaging Kit (RIBOBIO, Guangzhou, China). Briefly, cells were grown in 96-well plates and cultured to the normal growth stage. EdU labeling was carried out using 100 μL of reagent A. Cells were fixed using 4% paraformaldehyde (PFA) solution and eluted using Triton X-100, followed by Apollo and DAPI staining.

Cell transfection

Lentiviral vectors of Bach1 and Bach1 shRNA were purchased from GenePharma (Shanghai, China). Lung cancer cells were transduced with LV-Bach1 or LV-shBach1 in the presence of 8 µg/mL polybrene (GenePharma, Shanghai, China) for 48 h. Afterwards, a selection procedure using 10 µg/mL blasticidin for 72 h was performed. Surviving cells were collected and seeded into six-well plates.

Colony formation

Cells were grown at a density of 500 cells per well of a 6-well plate and maintained in RPMI 1640 medium supplemented with 10% FBS at 37 °C in a humidified atmosphere with 5% CO2. After two weeks, the cells were fixed by 4% PFA, and were stained with 0.1% crystal violet.

Cell invasion assay

Cell invasion was assessed using a Transwell chamber (8-μm pore size; Corning Co., Corning, USA) with Matrigel. At 48 h after transfection, cells were grown in the upper chamber with 10 μg/mL Matrigel. Culture medium containing 10% fetal bovine serum (FBS) was added to the lower chamber. After 48 h, the cells that migrated across the membrane were fixed using methanol, stained with 0.1% crystal violet, and counted under a microscope.

Flow cytometric analysis

For CD44 + cell analyses, cells were incubated with fluorescence-conjugated monoclonal antibodies against human CD44 (BD Biosciences, Franklin Lakes, NJ, USA). The samples were then analyzed using a FACS Aria III (BD Biosciences, Franklin Lakes, NJ, USA).

Western blot analysis

Total protein was isolated using a radioimmunoprecipitation assay lysis buffer. The extracted proteins were subjected to 10% SDS-PAGE and transferred to polyvinylidene fluoride membranes. The membranes were blocked with 5% milk and incubated with the primary antibodies at 4 °C overnight, followed by incubation with the corresponding horseradish peroxidase-conjugated secondary antibodies. The signals were detected using an enhanced chemiluminescence detection kit (Cell Signaling Technology, Danvers, MA, USA). The primary antibodies used were antibodies against Bach1 (1:1500, ab180853), CD44 (1:1500, ab189524), Sox2 (1:1500, ab92494), Nanog (1:1500, ab109250), Oct4 (1:1500, ab181557), p53 (1:1500, ab26), BCL2 (1:1500, ab32124), BAX (1:1500, ab32503), p-p38 MAPK and total p38 MAPK (Cell Signaling Technology, Boston, MA, USA), p-AKT1 (1:1500, phospho S473, ab81283), AKT1 (1:1500, ab28422), c-Fos (1:1500, ab190289), c-Jun (1:1500, ab32137 and GAPDH (1:1500, ab8245),all of which were obtained from Abcam.


Total RNA was isolated using TRIzol reagent (Invitrogen). Reverse transcription was performed using the PrimeScript RT Reagent Kit (Takara, Dalian, China). qRT-PCR was conducted using the SYBR Prime Script RT-PCR Kit (Takara). mRNA levels were calculated using the 2−ΔΔCt method [21]. The primers used are listed in Table 1.

Table 1 Primers used for real-time PCR

CD44 promoter analysis

Briefly, cells were transfected with Bach1-FLAG or a control plasmid. After 24 h, cells were transfected with a β-galactosidase plasmid and the wild-type or a mutated version of the CD44 promoter plasmid or the pGL3-basic luciferase reporter plasmid. Luciferase activity was determined using a Luciferase Assay Kit (Promega, Madison, WI, USA). β-galactosidase activity was also evaluated. The relative Luc activity was recorded as the ratio of Luc/β-gal activity.

Tumor spheroid formation assay

Cells were maintained in serum-free DMEM/F12 medium supplemented with 20 ng/mL epidermal growth factor, 20 ng/mL basic fibroblast growth factor, and B27. Afterwards, the cells were plated onto an ultra-low-attachment 24-well plate at a density of 5000 cells per well. Tumorsphere formation was photographed using a light microscope (Nikon, Japan).

Chromatin immunoprecipitation (ChIP) assay

Cells were grown in a 10-cm tissue culture dish. The next day, they were cross-linked with 1% formaldehyde for 10 min, followed by genomic DNA fragmentation. The chromatin fragments were immunoprecipitated with 5 μg of the antibody against Bach1 (R&D Systems, Minneapolis, MN, USA) or an antibody against CD44 (R&D Systems). DNA extraction was performed using a Qiagen Purification kit. Subsequently, real-time PCR analysis was conducted using primers amplifying the promoters of Sox2, Nanog, and Oct4.

Immunohistochemical (IHC) staining

Tissue sections obtained from xenografts were incubated with rabbit polyclonal anti-Ki-67 antibody at 4 °C overnight. Normal rabbit serum was used as a negative control. The cells were then incubated with a horseradish peroxidase-conjugated anti-rabbit secondary antibody (Santa Cruz, CA, USA) at 37 °C for 1 h. A diaminobenzidine substrate kit (Vector Laboratories, Burlingame, CA, USA) was used to develop the signals.

Xenograft experiments

All animal studies were approved by the Ethics Committee of the Experimental Research at Zhongshan Hospital, Fudan University. Six-week-old nude mice (six mice per group, grouped as CD44+, CD44− LV-NC, and LV-shBach1) were injected subcutaneously into the bilateral flank area with 5 × 106 cells in 200 μL PBS mixed with 100 μL of Matrigel. Tumor volume was recorded every three days. Then, the mice were sacrificed to harvest the tumor tissues for hematoxylin and eosin (HE) staining or IHC analysis. To perform the in vivo tumor metastasis assay, six nude mice per group were injected via caudal vein with 5 × 106 cells in 200 μL of PBS. Lung tissues were observed.

Statistical analysis

Data are presented as the mean ± standard error of at least three independent assays. SPSS 20.0 and GraphPad Prism v. 6.0 were used for statistical analysis. Two-group comparisons were conducted using Student’s t-test. One-way ANOVA was used to compare multiple groups. Statistical significance was set at P < 0.05.


Lung CSCs were successfully enriched from A549 and SPC-A1 cells

Recently, CD44 has been identified as a tumor-initiating CSC marker in various cancers. We isolated CD44+ lung cancer cells using flow cytometric analysis as shown in Fig. 1A, B (P < 0.001). As shown in Fig. 1C, D (P < 0.05), Bach1, CD44, Sox2, Nanog, and Oct4 protein expression was significantly increased in CD44 + A549 and SPC-A1 CSCs as evaluated using western blotting. We then confirmed the tumor growth of lung CSCs in xenografts. Mice were injected with CD44+ A549 and CD44− cells. As shown in Fig. 1E (P < 0.05), tumor volume was decreased in the CD44− mice group compared to the CD44+ group. As shown in Fig. 1F, the Ki-67 positive cell ratio was markedly increased in the CD44+ group. In contrast, as shown in Fig. 1G, Bach1 and CD44 protein expression was greatly elevated in the mice in the CD44+ group (P < 0.05).

Fig. 1
figure 1

Lung CSCs were successfully enriched from A549 and SPC-A1 cells. A, B Flow cytometric analysis results demonstrating the percentage of tumorigenic CD44+ A549 and SPC-A1 cells. C, D CD44+ A549 and SPC-A1 CSCs were analyzed using anti-Bach1, anti-CD44, anti-Sox2, anti-Nanog and anti-Oct4 antibodies using western blotting. E Tumor volume was shown in the two different groups. Mice were injected with CD44+ A549 and CD44− cells. F Ki-67-positive cell ratios. G Bach1 protein expression was evaluated using IHC western blot analysis. *P < 0.05, ***P < 0.001

Knockdown of Bach1 inhibited lung CSC proliferation, enhanced cell apoptosis, and repressed cell invasion

Moreover, to study the potential role of Bach1 in CSC growth, CD44+ cells were transfected with LV-shBach1 for 48 h. The EdU assay was performed 48 h post-transfection and it was observed that cell proliferation was repressed upon treatment with LV-shBach1, as shown in Fig. 2A (P < 0.05). Figure 2B (P < 0.05) shows that cell colony formation capacity was also reduced with the loss of Bach1. In addition, apoptosis was triggered by LV-shBach1, as shown in Fig. 2C (P < 0.05). In Fig. 2D, we checked apoptosis related gene panels including p53, BCL2 and BAX. We found that BCL2 protein expression were reduced by Bach1 shRNA while BAX and p53 were induced by Bach1 shRNA. The Transwell invasion assay showed that cell invasion ability was suppressed by a lack of Bach1 (Fig. 2E, P < 0.05).

Fig. 2
figure 2

Role of Bach1 in lung CSC proliferation, apoptosis, and invasion. CD44 + cells were cultured at 70% confluency and transfected with LV-shBach1 for 48 h. A The EdU assay was performed 48 h post-transfection to determine cell proliferation. B A colony formation assay was performed to assess cell colony formation capacity. C Flow cytometry was utilized to detect cell apoptosis. D p53, BCL2 and BAX protein expression in lung CSCs. E A Transwell invasion assay was performed to determine cell invasion ability. *P < 0.05; **P < 0.01

Knockdown of Bach1 restrained lung CSC properties

Next, we proved that CD44, Sox2, Nanog, and Oct4 mRNA and protein expression in lung CSCs was greatly inhibited by LV-shBach1 (Fig. 3A, B, P < 0.05). As shown in Fig. 3C (P < 0.05), the tumor spheroid assay indicated that cell sphere formation was remarkably reduced by the loss of Bach1. ChIP-qPCR was also performed (Fig. 3D, P < 0.05) revealing that Bach1 and CD44 co-occupied the promoters of CSC-related genes, as determined using anti-Bach1 or anti-CD44 antibodies. Furthermore, overexpression of Bach1 significantly increased the luciferase activity of the CD44 promoter (Fig. 3E, P < 0.05).

Fig. 3
figure 3

Role of Bach1 in the determination of lung CSC properties. A CD44, Sox2, Nanog, and Oct4 mRNA expression in lung CSCs. B CD44, Sox2, Nanog, and Oct4 protein expression in lung CSCs. C A tumor spheroid assay was carried out to evaluate cell sphere formation ability. D ChIP-qPCR was conducted using anti-Bach1 or anti-CD44 antibodies. E Analysis of CD44 promoter activity. Cells were transfected with a Bach1-FLAG plasmid for 24 h. *P < 0.05

Bach1 loss repressed the tumor growth and tumor metastasis of lung CSCs

Mice were injected with CD44 + A549 cells transfected with or without Bach1. It was revealed that the tumor growth of lung CSCs in xenografts was significantly reduced after treatment with LV-shBach1 (Fig. 4A). As shown in Fig. 4B, C (P < 0.05), tumor volume and weight were both decreased with the loss of Bach1 in vivo. IHC staining for Ki-67 is shown in Fig. 4D. To carry out the in vivo tumor metastasis assay, six nude mice per group were injected via caudal vein with 5 × 106 CD44 + A549 cells transfected with or without Bach1cells in 200 μL of PBS. As shown in Fig. 4E (P < 0.05), the loss of Bach1 inhibited the metastasis of lung CSCs in xenografts as evaluated using the HE assay.

Fig. 4
figure 4

Role of Bach1 on the growth and metastasis of lung CSCs. A PET-CT was utilized to observe the tumor growth of lung CSCs in xenografts. B Tumor volume change over time. C Tumor weight. D IHC staining of Ki-67. E Loss of Bach1 inhibited the metastasis of lung CSCs in xenografts as evaluated using the HE assay. HE-stained metastasized lung tissues from mice are shown. *P < 0.05

Relation of MAPK signaling with lung CSCs

Moreover, microarray analysis was performed to explore the underlying molecular mechanisms of Bach1. Gene expression in A549 CSCs transfected with LV-NC or LV-shBach1 was analyzed using RNA sequencing. A volcano plot of the data showing altered gene expression in A549 CSCs transfected with or without LV-shBach1 is presented in Fig. 5A. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway indicated the functions and signaling pathways associated with the target genes [22]. KEGG pathway analysis indicated the close association between Bach1 and the MAPK signaling pathway, as shown in Fig. 5B, C. Figure 5D shows the top 20 genes involved in the MAPK signaling pathway. We proved that p-p38, p-AKT1, c-Fos and c-Jun protein expression was significantly decreased upon treatment with LV-shBach1 (Fig. 5E, F, P < 0.05).

Fig. 5
figure 5

Relationship of MAPK signaling and lung CSCs. Microarray analysis was applied to screen the mRNAs which can be regulated by Bach1. A Volcano plot of the data showing altered gene expression in A549 CSCs transfected with or without LV-shBach1. B, C KEGG pathway analysis revealed the signaling pathways potentially involved in Bach1-mediated functions. D Top 20 genes involved in the MAPK signaling pathway. E, F p-p38, p-AKT1, c-Fos and c-Jun protein expression

Inhibitors of MAPK signaling repressed CD44 + CSC characteristics

LY2228820 is commonly used as a MAPK inhibitor. Results of the colony formation assay implied that A549 CSC colony formation capacity was induced upon overexpression of Bach1, while LY2228820 repressed this process (Fig. 6A, P < 0.05). Consistently, cell invasion ability was also reduced by MAPK inhibitors (Fig. 6B, P < 0.05). Additionally, results of the tumor spheroid assay revealed that LY2228820 suppressed cell sphere formation, as shown in Fig. 6C. As shown in Fig. 6D (P < 0.05), Bach1, CD44, and p-p-38 protein expression triggered by LV-Bach1 was greatly reduced by LY2228820 in A549 CSCs.

Fig. 6 
figure 6

Inhibitors of MAPK signaling repressed CD44 + CSC characteristics. A Colony formation capacity. B A Transwell invasion assay was carried out to test cell invasion ability. C A tumor spheroid assay was performed to evaluate cell sphere formation ability. D Bach1, CD44, and p-p-38 protein expression in A549 CSCs. *P < 0.05


Patients with lung cancer whose tumors have undergone metastasis have low survival rates [23]. Mounting evidence indicates that CSCs are mainly responsible for cancer aggressiveness, drug resistance, and tumor relapse. Studies of genes involved in lung CSCs are critical for understanding their therapeutic potential. In the present study, the effect of Bach1 on the progression of lung CSCs was determined. To our knowledge, this is the first study to report the potential mechanism of Bach1 in lung CSCs. Loss of Bach1 markedly reduced growth, invasion, and CSC-like properties in lung CSCs in vivo and in vitro by activating CD44 expression. In addition, we found that the knockdown of Bach1 inactivated the MAPK signaling pathway.

Accumulating evidence has shown that Bach1 contributes to tumor metastasis [15]. For example, knockdown of the Bach1 gene suppresses the invasion of breast cancer cells by targeting the expression levels of matrix metalloproteinase-9 and CXCR4 receptor [24]. Bach1 silencing significantly inhibited the migration of colon cancer cells by inhibiting metastasis-related genes [25]. It has been shown that Bach1 can form a complex with MAFG and the DNA methyltransferase DNMT3B, which resulted in the repression of tumor suppressor genes [26, 27]. It has been reported that Bach1 can interact with Nanog, Sox2, and Oct4, thereby maintaining stem cell identity and self-renewal of human embryonic stem cells [28]. In the present study, we observed that Bach1 was highly expressed in lung CSCs. The upregulation of Bach1 in lung CSCs may be associated with an increase in the expression of CSC-associated genes. However, the specific mechanisms underlying the elevation of Bach1 in lung CSCs have yet to be investigated. Previously, we reported that chronic intermittent hypoxia induced lung cancer stem cell-like properties through enhancing Bach1 expression [29]. In addition, we would further check the detailed mechanism that Bach1 induces lung tumor growth and reduces lung cancer cell death. For example, as reported, Bach1 can mediate suppression of p53 is inhibited by p19(ARF) independently of MDM2 [30]. In glioblastoma, Bach1 promotes temozolomide resistance through antagonizing the function of p53 [17].

Emerging roles of CD44 have been demonstrated in CSCs and show that it may be a promising biomarker for different types of cancers [31]. Mounting evidence has shown that CD44 is a crucial CSC marker and is critical in regulating cancer cell self-renewal, tumor initiation, and metastasis. Therefore, CD44 is widely used to enrich CSCs through fluorescence-activated cell sorting of dissociated single cells [32]. It has been reported that lung cancer cells expressing CD44 have enriched CSC properties [33]. In the present study, single cells were isolated from A549 and SPC-A1 tumor cell cultures. We found that Bach1 expression was increased in lung CSCs and was positively correlated with CSC-related gene expression in lung CSCs. In addition, we proved that the loss of Bach1 greatly reduced the expression of the CSC-related genes Sox2, Nanog, and Oct4; however, the relationship between CD44 and Bach1 remains unknown. A positive correlation between CD44 expression and Bach1 levels has been observed in lung CSCs. In addition, the loss of Bach1 was able to repress CD44 expression. Subsequently, we confirmed that CD44 is a binding partner of Bach1 in lung CSCs. More studies are needed to explore the correlation between CD44 and Bach1 in lung CSCs.

The MAPK signaling pathway is an important signaling cascade that can promote cell survival and differentiation [34,35,36]. Activation of the MAPK signaling pathway plays a positive role in tumor metastasis in numerous human malignancies, including lung cancer [37]. The lncRNA TUC338 can promote the invasion of lung cancer through the MAPK pathway [38]. In addition, lncRNA SNHG12 triggers multidrug resistance by activating the MAPK/Slug pathway in lung cancer [39]. Further studies have revealed that CD44 acts as an ERK-dependent downstream effector of serglycin, which can activate the MAPK/β-catenin axis to induce CD44 receptor expression in nasopharyngeal carcinoma [40]. CD44 can regulate a number of central signaling pathways, including the PI3K/AKT, Rho GTPase, and Ras-MAPK pathways [41]. In our study, we found that Bach1 silencing significantly repressed the MAPK pathway. Hence, we showed the relationship of the MAPK signaling pathway and Bach1 in promoting lung CSC growth and CSC-like properties. We also proved that MAPK inhibitors reversed CSC growth and CSC-like characteristics induced by the overexpression of Bach1. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling can promote chemoresistance, progression and stemness through regulating the expression of CD44 in oral cancer [42]. However, the downstream target proteins of MAPK signaling that are linked to CD44+ should be explored in a future study. Among MAPK gene panels, p-p38, p-AKT1, c-Fos and c-Jun were evaluated and we found p-p38, p-AKT1, c-Fos and c-Jun protein expression was reduced by loss of Bach1.

In conclusion, these results demonstrated that silencing Bach1 played a critical role in the growth of lung CSCs, suppressing cell proliferation and promoting cell apoptosis via activating CD44 and MAPK pathway. Therefore, our research exerted far-reaching significance in developing promising therapy for lung cancer patients.

Availability of data and materials

The data that support the findings in this study are available from the corresponding author upon reasonable request.


  1. 1.

    Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 2010;10(11):760–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Wei L, Sun JJ, Cui YC, Jiang SL, Wang XW, Lv LY, et al. Twist may be associated with invasion and metastasis of hypoxic NSCLC cells. Tumour Biol J Int Soc Oncodev Biol Med. 2016;37(7):9979–87.

    CAS  Google Scholar 

  3. 3.

    Prabhu VV, Devaraj SN. KAI1/CD82, metastasis suppressor gene as a therapeutic target for non-small-cell lung carcinoma. J Environ Pathol Toxicol Oncol Off Organ Int Soc Environ Toxicol Cancer. 2017;36(3):269–75.

    Google Scholar 

  4. 4.

    Tan BT, Park CY, Ailles LE, Weissman IL. The cancer stem cell hypothesis: a work in progress. Laboratory investigation. J Tech Methods Pathol. 2006;86(12):1203–7.

    CAS  Google Scholar 

  5. 5.

    Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730–7.

    CAS  PubMed  Google Scholar 

  6. 6.

    Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15(3):504–14.

    CAS  PubMed  Google Scholar 

  7. 7.

    Yi SY, Nan KJ. Tumor-initiating stem cells in liver cancer. Cancer Biol Ther. 2008;7(3):325–30.

    CAS  PubMed  Google Scholar 

  8. 8.

    Li C, Lee CJ, Simeone DM. Identification of human pancreatic cancer stem cells. Methods Mol Biol. 2009;568:161–73.

    CAS  PubMed  Google Scholar 

  9. 9.

    Su J, Wu S, Wu H, Li L, Guo T. CD44 is functionally crucial for driving lung cancer stem cells metastasis through Wnt/beta-catenin-FoxM1-Twist signaling. Mol Carcinog. 2016;55(12):1962–73.

    CAS  PubMed  Google Scholar 

  10. 10.

    Jiang P, Xu C, Chen L, Chen A, Wu X, Zhou M, et al. EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells. Mol Carcinog. 2018;57(12):1835–44.

    CAS  PubMed  Google Scholar 

  11. 11.

    Jiang P, Xu H, Xu C, Chen A, Chen L, Zhou M, et al. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway. Chem Biol Interact. 2018;296:154–61.

    CAS  PubMed  Google Scholar 

  12. 12.

    Zenke-Kawasaki Y, Dohi Y, Katoh Y, Ikura T, Ikura M, Asahara T, et al. Heme induces ubiquitination and degradation of the transcription factor Bach1. Mol Cell Biol. 2007;27(19):6962–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Warnatz HJ, Schmidt D, Manke T, Piccini I, Sultan M, Borodina T, et al. The BTB and CNC homology 1 (BACH1) target genes are involved in the oxidative stress response and in control of the cell cycle. J Biol Chem. 2011;286(26):23521–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Zhou Y, Wu H, Zhao M, Chang C, Lu Q. The Bach family of transcription factors: a comprehensive review. Clin Rev Allergy Immunol. 2016;50(3):345–56.

    CAS  PubMed  Google Scholar 

  15. 15.

    Davudian S, Mansoori B, Shajari N, Mohammadi A, Baradaran B. BACH1, the master regulator gene: a novel candidate target for cancer therapy. Gene. 2016;588(1):30–7.

    CAS  PubMed  Google Scholar 

  16. 16.

    Liang Y, Wu H, Lei R, Chong RA, Wei Y, Lu X, et al. Transcriptional network analysis identifies BACH1 as a master regulator of breast cancer bone metastasis. J Biol Chem. 2012;287(40):33533–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Nie E, Jin X, Wu W, Yu T, Zhou X, Zhi T, et al. BACH1 promotes temozolomide resistance in glioblastoma through antagonizing the function of p53. Sci Rep. 2016;6:39743.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Shirjang S, Mansoori B, Mohammadi A, Shajari N, Duijf PHG, Najafi S, et al. miR-330 regulates colorectal cancer oncogenesis by targeting BACH1. Adv Pharmaceut Bull. 2020;10(3):444–51.

    CAS  Google Scholar 

  19. 19.

    Lignitto L, LeBoeuf SE, Homer H, Jiang S, Askenazi M, Karakousi TR, et al. Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1. Cell. 2019;178(2):316-29e18.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Wiel C, Le Gal K, Ibrahim MX, Jahangir CA, Kashif M, Yao H, et al. BACH1 stabilization by antioxidants stimulates lung cancer metastasis. Cell. 2019;178(2):330-45e22.

    CAS  PubMed  Google Scholar 

  21. 21.

    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8.

    CAS  Google Scholar 

  22. 22.

    Yang G, Zhang Y, Yang J. Identification of potentially functional CircRNA-miRNA-mRNA regulatory network in gastric carcinoma using bioinformatics analysis. Med Sci Monit Int Med J Exp Clin Res. 2019;25:8777–96.

    CAS  Google Scholar 

  23. 23.

    Wang X, Adjei AA. Lung cancer and metastasis: new opportunities and challenges. Cancer Metastasis Rev. 2015;34(2):169–71.

    CAS  PubMed  Google Scholar 

  24. 24.

    Mohammadzadeh R, Saeid Harouyan M, Ale Taha SM. Silencing of bach1 gene by small interfering RNA-mediation regulates invasive and expression level of miR-203, miR-145, matrix metalloproteinase-9, and CXCR4 receptor in MDA-MB-468 breast cancer cells. Tumour Biol J Int Soc Oncodev Biol Med. 2017;39(3):1010428317695925.

    Google Scholar 

  25. 25.

    Davudian S, Shajari N, Kazemi T, Mansoori B, Salehi S, Mohammadi A, et al. BACH1 silencing by siRNA inhibits migration of HT-29 colon cancer cells through reduction of metastasis-related genes. Biomed Pharmacother. 2016;84:191–8.

    CAS  PubMed  Google Scholar 

  26. 26.

    Fang M, Ou J, Hutchinson L, Green MR. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype. Mol Cell. 2014;55(6):904–15.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Fang M, Hutchinson L, Deng A, Green MR. Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma. Proc Natl Acad Sci USA. 2016;113(5):1250–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Wei X, Guo J, Li Q, Jia Q, Jing Q, Li Y, et al. Bach1 regulates self-renewal and impedes mesendodermal differentiation of human embryonic stem cells. Sci Adv. 2019;5(3):eaau7887.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Hao S, Zhu X, Liu Z, Wu X, Li S, Jiang P, et al. Chronic intermittent hypoxia promoted lung cancer stem cell-like properties via enhancing Bach1 expression. Respir Res. 2021;22(1):58.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Nishizawa H, Ota K, Dohi Y, Ikura T, Igarashi K. Bach1-mediated suppression of p53 is inhibited by p19(ARF) independently of MDM2. Cancer Sci. 2012;103(5):897–903.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Yan Y, Zuo X, Wei D. Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med. 2015;4(9):1033–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Wang L, Zuo X, Xie K, Wei D. The role of CD44 and cancer stem cells. Methods Mol Biol. 2018;1692:31–42.

    CAS  PubMed  Google Scholar 

  33. 33.

    Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS ONE. 2010;5(11):e14062.

    PubMed  PubMed Central  Google Scholar 

  34. 34.

    Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochem Biophys Acta. 2010;1802(4):396–405.

    CAS  PubMed  Google Scholar 

  35. 35.

    Vincent JM, Wack RP, Person DA, Bass JW. Pertussis as the cause of recurrent bradycardia in a young infant. Pediatr Infect Dis J. 1991;10(4):340–2.

    CAS  PubMed  Google Scholar 

  36. 36.

    Xu Y, Li N, Xiang R, Sun P. Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence. Trends Biochem Sci. 2014;39(6):268–76.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L, et al. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers. 2019;11(10).

  38. 38.

    Zhang YX, Yuan J, Gao ZM, Zhang ZG. LncRNA TUC338 promotes invasion of lung cancer by activating MAPK pathway. Eur Rev Med Pharmacol Sci. 2018;22(2):443–9.

    PubMed  Google Scholar 

  39. 39.

    Wang P, Chen D, Ma H, Li Y. LncRNA SNHG12 contributes to multidrug resistance through activating the MAPK/Slug pathway by sponging miR-181a in non-small cell lung cancer. Oncotarget. 2017;8(48):84086–101.

    PubMed  PubMed Central  Google Scholar 

  40. 40.

    Chu Q, Huang H, Huang T, Cao L, Peng L, Shi S, et al. Extracellular serglycin upregulates the CD44 receptor in an autocrine manner to maintain self-renewal in nasopharyngeal carcinoma cells by reciprocally activating the MAPK/beta-catenin axis. Cell Death Dis. 2016;7(11):e2456.

    PubMed  PubMed Central  Google Scholar 

  41. 41.

    Ouhtit A, Rizeq B, Saleh HA, Rahman MM, Zayed H. Novel CD44-downstream signaling pathways mediating breast tumor invasion. Int J Biol Sci. 2018;14(13):1782–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Kashyap T, Pramanik KK, Nath N, Mishra P, Singh AK, Nagini S, et al. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3beta signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer. Oral Oncol. 2018;86:234–43.

    CAS  PubMed  Google Scholar 

Download references


Thanks for the support and contributions of participators.


This work was supported by the by Grants from The National Key Research and Development Program of China (No. 2018YFC1313600). This work was supported by Grants from Research Fund of Shanghai Municipal Health Commission (No. 2019ZB0105).

Author information




PJ, ZL and FL conceived and designed research; PJ, SH, FL and ZL conducted experiments; PJ, SH, FL and ZL analyzed data; SH, FL and ZL interpreted data of experiments; PJ, FL and ZL prepared figures; PJ and SH drafted manuscript; PJ, FL and ZL edited and revised manuscript; SL and JG approved final version of manuscript and provided fund acquisition. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Shengyu Hao, Jian Gao or Shanqun Li.

Ethics declarations

Ethics approval and consent to participate

All animal procedures in this study were approved by the Experimental Animal Ethics Committee of Zhongshan Hospital, Fudan University and carried out in accordance with the guidelines for the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jiang, P., Li, F., Liu, Z. et al. BTB and CNC homology 1 (Bach1) induces lung cancer stem cell phenotypes by stimulating CD44 expression. Respir Res 22, 320 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Bach1
  • Lung cancer stem cells
  • CD44
  • MAPK signaling pathway